Key Summary
- A specific batch of a chemotherapy medicine has been recalled as a precaution after a quality concern was spotted in testing.
- No patient harm or side effects have been reported so far, and the recall is classed as low risk.
- Patients don’t need to take any action, but healthcare staff have been told to stop using and return the affected stock.
Accord Healthcare has recalled a batch of the chemotherapy drug Carmustine 100mg Powder and Solvent for Concentrate for Solution for Infusion (1 vial 100mg powder, 1 vial of 3 mL solvent) as a precautionary move due to safety concerns.
The decision was made as the experts observed the presence of a non-volatile residue during Official Medicines Control Laboratory (OMCL) testing.
The drug was recalled under a Class 2 medicines recall and no cases of patients suffering from adverse reactions are recorded yet.
The medicine of batch number M2408383 and pack size 100mg/3mL per vial, first distributed on 16 June, 2025 is recalled.
Health professionals who have received this batch have been advised to stop supplying them and quarantine the stocks until they are able to return it to the suppliers.
As the product is administered only by healthcare professionals, patients are not required to take any action.
Patients who have administered medicines from this batch need not do anything as this is a precautionary measure.
In case of any adverse reaction, they can seek immediate medical attention and report the incident to the MHRA Yellow Card Scheme.
